
NATURE . COM {
}
Title:
Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity | Oncogene
Description:
The present study addresses the effect of targeting type I insulin-like growth factor receptor (IGF-IR) with antisense strategies in in vivo growth of breast cancer cells. Our research was carried out on C4HD tumors from an experimental model of hormonal carcinogenesis in which the synthetic progestin medroxyprogesterone acetate (MPA) induced mammary adenocarcinomas in Balb/c mice. We employed two different experimental strategies. With the first one we demonstrated that direct intratumor injection of phosphorothioate antisense oligodeoxynucleotides (AS[S]ODNs) to IGF-IR mRNA resulted in a significant inhibition of C4HD tumor growth. In the second experimental strategy, we assessed the effect of intravenous (i.v.) injection of AS [S]ODN on C4HD tumor growth. This systemic treatment also resulted in significant reduction in tumor growth. The antitumor effect of IGF-IR AS[S]ODNs in both experimental protocols was due to a specific antisense mechanism, since growth inhibition was dose-dependent and no abrogation of tumor proliferation was observed in mice treated with phosphorothioate sense ODNs (S[S]ODNs). In addition, IGF-IR expression was inhibited in tumors from mice receiving AS[S]ODNs, as compared to tumors from control groups. We then investigated signal transduction pathways modulated in vivo by AS[S]ODNs treatment. Tumors from AS[S]ODN-treated mice of both intratumoral and intravenous protocols showed a significant decrease in the degree of insulin receptor substrate-1 (IRS-1) tyrosine phosphorylation. Activation of two of the main IGF-IR signaling pathways, phosphatidylinositol 3-kinase (PI-3K)/Akt and p42/p44 mitogen-activated protein kinases (MAPK) was abolished in tumors growing in AS[S]ODN-treated animals. Moreover, ErbB-2 tyrosine phosphorylation was blocked by in vivo administration of AS[S]ODNs. On the other hand, we found no regulation of either progesterone receptor expression or activity by in vivo AS[S]ODNs administration. Our results for the first time demonstrated that breast cancer growth can be inhibited by direct in vivo administration of IGF-IR AS[S]ODNs.
Website Age:
30 years and 10 months (reg. 1994-08-11).
Matching Content Categories {📚}
- Social Networks
- Education
- Science
Content Management System {📝}
What CMS is nature.com built with?
Custom-built
No common CMS systems were detected on Nature.com, and no known web development framework was identified.
Traffic Estimate {📈}
What is the average monthly size of nature.com audience?
🌠 Phenomenal Traffic: 5M - 10M visitors per month
Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.
check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush
How Does Nature.com Make Money? {💸}
Display Ads {🎯}
The website utilizes display ads within its content to generate revenue. Check the next section for further revenue estimates.
Ads are managed by yourbow.com. Particular relationships are as follows:
Direct Advertisers (10)
google.com, pmc.com, doceree.com, yourbow.com, audienciad.com, onlinemediasolutions.com, advibe.media, aps.amazon.com, getmediamx.com, onomagic.comReseller Advertisers (38)
conversantmedia.com, rubiconproject.com, pubmatic.com, appnexus.com, openx.com, smartadserver.com, lijit.com, sharethrough.com, video.unrulymedia.com, google.com, yahoo.com, triplelift.com, onetag.com, sonobi.com, contextweb.com, 33across.com, indexexchange.com, media.net, themediagrid.com, adform.com, richaudience.com, sovrn.com, improvedigital.com, freewheel.tv, smaato.com, yieldmo.com, amxrtb.com, adyoulike.com, adpone.com, criteo.com, smilewanted.com, 152media.info, e-planning.net, smartyads.com, loopme.com, opera.com, mediafuse.com, betweendigital.comHow Much Does Nature.com Make? {💰}
Display Ads {🎯}
$63,100 per month
According to our algorithms, Nature.com's monthly online income from display advertising ranges from $42,042 to $115,616.
Keywords {🔍}
cancer, breast, res, nature, mol, growth, elizalde, access, baserga, article, biol, oncogene, receptor, cell, content, vivo, igfir, research, assodns, natl, sci, cookies, antisense, charreau, tumor, proc, acad, usa, endocrinology, privacy, progesterone, salatino, tumors, experimental, open, rubin, lee, lange, data, inhibition, signaling, pathways, proietti, mice, chem, ilan, endocrinol, coppola, sell, horwitz,
Topics {✒️}
nature portfolio permissions reprints privacy policy nature advertising scientific promotion social media author information authors research igf-1r antibody cixutumumab author correspondence igf-ir mrna resulted erbb-2-positive breast cancer insulin receptor substrate-1 growth factor receptor personal data springerlink instant access instituto de biología progesterone receptor expression progesterone receptor activity data protection permissions breast cancer growth cancer gene ther isabel frahm induced mammary adenocarcinomas breast cancer cells privacy igf-ir expression c4hd tumor growth tumor-suppressor mir-16 breast cancer res explore content subscription content kull jr fc specific antisense mechanism european economic area present study addresses institutional subscriptions read e3 ligase nedd4 sanatorio mater dei accepting optional cookies myers jr mg roberts jr ct journals search log phosphorothioate antisense oligodeoxynucleotides ignar-trowbridge dm overcomes trastuzumab resistance cordo russow béguelinp article salatino
Questions {❓}
- Nuclear ErbB-2: a Novel Therapeutic Target in ErbB-2-Positive Breast Cancer?
Schema {🗺️}
WebPage:
mainEntity:
headline:Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity
description:The present study addresses the effect of targeting type I insulin-like growth factor receptor (IGF-IR) with antisense strategies in in vivo growth of breast cancer cells. Our research was carried out on C4HD tumors from an experimental model of hormonal carcinogenesis in which the synthetic progestin medroxyprogesterone acetate (MPA) induced mammary adenocarcinomas in Balb/c mice. We employed two different experimental strategies. With the first one we demonstrated that direct intratumor injection of phosphorothioate antisense oligodeoxynucleotides (AS[S]ODNs) to IGF-IR mRNA resulted in a significant inhibition of C4HD tumor growth. In the second experimental strategy, we assessed the effect of intravenous (i.v.) injection of AS [S]ODN on C4HD tumor growth. This systemic treatment also resulted in significant reduction in tumor growth. The antitumor effect of IGF-IR AS[S]ODNs in both experimental protocols was due to a specific antisense mechanism, since growth inhibition was dose-dependent and no abrogation of tumor proliferation was observed in mice treated with phosphorothioate sense ODNs (S[S]ODNs). In addition, IGF-IR expression was inhibited in tumors from mice receiving AS[S]ODNs, as compared to tumors from control groups. We then investigated signal transduction pathways modulated in vivo by AS[S]ODNs treatment. Tumors from AS[S]ODN-treated mice of both intratumoral and intravenous protocols showed a significant decrease in the degree of insulin receptor substrate-1 (IRS-1) tyrosine phosphorylation. Activation of two of the main IGF-IR signaling pathways, phosphatidylinositol 3-kinase (PI-3K)/Akt and p42/p44 mitogen-activated protein kinases (MAPK) was abolished in tumors growing in AS[S]ODN-treated animals. Moreover, ErbB-2 tyrosine phosphorylation was blocked by in vivo administration of AS[S]ODNs. On the other hand, we found no regulation of either progesterone receptor expression or activity by in vivo AS[S]ODNs administration. Our results for the first time demonstrated that breast cancer growth can be inhibited by direct in vivo administration of IGF-IR AS[S]ODNs.
datePublished:2004-05-03T00:00:00Z
dateModified:2004-05-03T00:00:00Z
pageStart:5161
pageEnd:5174
sameAs:https://doi.org/10.1038/sj.onc.1207659
keywords:
breast cancer
IGF-IR
antisense strategies
Medicine/Public Health
general
Internal Medicine
Cell Biology
Human Genetics
Oncology
Apoptosis
image:
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.onc.1207659/MediaObjects/41388_2004_Article_BF1207659_Fig1_HTML.jpg
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.onc.1207659/MediaObjects/41388_2004_Article_BF1207659_Fig2_HTML.gif
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.onc.1207659/MediaObjects/41388_2004_Article_BF1207659_Fig3_HTML.gif
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.onc.1207659/MediaObjects/41388_2004_Article_BF1207659_Fig4_HTML.jpg
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.onc.1207659/MediaObjects/41388_2004_Article_BF1207659_Fig5_HTML.jpg
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.onc.1207659/MediaObjects/41388_2004_Article_BF1207659_Fig6_HTML.jpg
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.onc.1207659/MediaObjects/41388_2004_Article_BF1207659_Fig7_HTML.jpg
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.onc.1207659/MediaObjects/41388_2004_Article_BF1207659_Fig8_HTML.jpg
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.onc.1207659/MediaObjects/41388_2004_Article_BF1207659_Fig9_HTML.jpg
isPartOf:
name:Oncogene
issn:
1476-5594
0950-9232
volumeNumber:23
type:
Periodical
PublicationVolume
publisher:
name:Nature Publishing Group UK
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:Mariana Salatino
affiliation:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490
address:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490, Buenos Aires, Argentina
type:PostalAddress
type:Organization
type:Person
name:Roxana Schillaci
affiliation:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490
address:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490, Buenos Aires, Argentina
type:PostalAddress
type:Organization
type:Person
name:Cecilia J Proietti
affiliation:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490
address:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490, Buenos Aires, Argentina
type:PostalAddress
type:Organization
type:Person
name:Romina Carnevale
affiliation:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490
address:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490, Buenos Aires, Argentina
type:PostalAddress
type:Organization
type:Person
name:Isabel Frahm
affiliation:
name:Servicio de PatologÃa, Sanatorio Mater Dei
address:
name:Servicio de PatologÃa, Sanatorio Mater Dei, Buenos Aires, Argentina
type:PostalAddress
type:Organization
type:Person
name:Alfredo A Molinolo
affiliation:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490
address:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490, Buenos Aires, Argentina
type:PostalAddress
type:Organization
type:Person
name:Adolfo Iribarren
affiliation:
name:Instituto de Investigaciones en IngenierÃa Genética y BiologÃa Molecular (INGEBI)
address:
name:Instituto de Investigaciones en IngenierÃa Genética y BiologÃa Molecular (INGEBI), Argentina
type:PostalAddress
type:Organization
type:Person
name:Eduardo H Charreau
affiliation:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490
address:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490, Buenos Aires, Argentina
type:PostalAddress
type:Organization
type:Person
name:Patricia V Elizalde
affiliation:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490
address:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490, Buenos Aires, Argentina
type:PostalAddress
type:Organization
email:[email protected]
type:Person
isAccessibleForFree:
hasPart:
isAccessibleForFree:
cssSelector:.main-content
type:WebPageElement
type:ScholarlyArticle
context:https://schema.org
ScholarlyArticle:
headline:Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity
description:The present study addresses the effect of targeting type I insulin-like growth factor receptor (IGF-IR) with antisense strategies in in vivo growth of breast cancer cells. Our research was carried out on C4HD tumors from an experimental model of hormonal carcinogenesis in which the synthetic progestin medroxyprogesterone acetate (MPA) induced mammary adenocarcinomas in Balb/c mice. We employed two different experimental strategies. With the first one we demonstrated that direct intratumor injection of phosphorothioate antisense oligodeoxynucleotides (AS[S]ODNs) to IGF-IR mRNA resulted in a significant inhibition of C4HD tumor growth. In the second experimental strategy, we assessed the effect of intravenous (i.v.) injection of AS [S]ODN on C4HD tumor growth. This systemic treatment also resulted in significant reduction in tumor growth. The antitumor effect of IGF-IR AS[S]ODNs in both experimental protocols was due to a specific antisense mechanism, since growth inhibition was dose-dependent and no abrogation of tumor proliferation was observed in mice treated with phosphorothioate sense ODNs (S[S]ODNs). In addition, IGF-IR expression was inhibited in tumors from mice receiving AS[S]ODNs, as compared to tumors from control groups. We then investigated signal transduction pathways modulated in vivo by AS[S]ODNs treatment. Tumors from AS[S]ODN-treated mice of both intratumoral and intravenous protocols showed a significant decrease in the degree of insulin receptor substrate-1 (IRS-1) tyrosine phosphorylation. Activation of two of the main IGF-IR signaling pathways, phosphatidylinositol 3-kinase (PI-3K)/Akt and p42/p44 mitogen-activated protein kinases (MAPK) was abolished in tumors growing in AS[S]ODN-treated animals. Moreover, ErbB-2 tyrosine phosphorylation was blocked by in vivo administration of AS[S]ODNs. On the other hand, we found no regulation of either progesterone receptor expression or activity by in vivo AS[S]ODNs administration. Our results for the first time demonstrated that breast cancer growth can be inhibited by direct in vivo administration of IGF-IR AS[S]ODNs.
datePublished:2004-05-03T00:00:00Z
dateModified:2004-05-03T00:00:00Z
pageStart:5161
pageEnd:5174
sameAs:https://doi.org/10.1038/sj.onc.1207659
keywords:
breast cancer
IGF-IR
antisense strategies
Medicine/Public Health
general
Internal Medicine
Cell Biology
Human Genetics
Oncology
Apoptosis
image:
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.onc.1207659/MediaObjects/41388_2004_Article_BF1207659_Fig1_HTML.jpg
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.onc.1207659/MediaObjects/41388_2004_Article_BF1207659_Fig2_HTML.gif
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.onc.1207659/MediaObjects/41388_2004_Article_BF1207659_Fig3_HTML.gif
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.onc.1207659/MediaObjects/41388_2004_Article_BF1207659_Fig4_HTML.jpg
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.onc.1207659/MediaObjects/41388_2004_Article_BF1207659_Fig5_HTML.jpg
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.onc.1207659/MediaObjects/41388_2004_Article_BF1207659_Fig6_HTML.jpg
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.onc.1207659/MediaObjects/41388_2004_Article_BF1207659_Fig7_HTML.jpg
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.onc.1207659/MediaObjects/41388_2004_Article_BF1207659_Fig8_HTML.jpg
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.onc.1207659/MediaObjects/41388_2004_Article_BF1207659_Fig9_HTML.jpg
isPartOf:
name:Oncogene
issn:
1476-5594
0950-9232
volumeNumber:23
type:
Periodical
PublicationVolume
publisher:
name:Nature Publishing Group UK
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:Mariana Salatino
affiliation:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490
address:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490, Buenos Aires, Argentina
type:PostalAddress
type:Organization
type:Person
name:Roxana Schillaci
affiliation:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490
address:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490, Buenos Aires, Argentina
type:PostalAddress
type:Organization
type:Person
name:Cecilia J Proietti
affiliation:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490
address:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490, Buenos Aires, Argentina
type:PostalAddress
type:Organization
type:Person
name:Romina Carnevale
affiliation:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490
address:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490, Buenos Aires, Argentina
type:PostalAddress
type:Organization
type:Person
name:Isabel Frahm
affiliation:
name:Servicio de PatologÃa, Sanatorio Mater Dei
address:
name:Servicio de PatologÃa, Sanatorio Mater Dei, Buenos Aires, Argentina
type:PostalAddress
type:Organization
type:Person
name:Alfredo A Molinolo
affiliation:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490
address:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490, Buenos Aires, Argentina
type:PostalAddress
type:Organization
type:Person
name:Adolfo Iribarren
affiliation:
name:Instituto de Investigaciones en IngenierÃa Genética y BiologÃa Molecular (INGEBI)
address:
name:Instituto de Investigaciones en IngenierÃa Genética y BiologÃa Molecular (INGEBI), Argentina
type:PostalAddress
type:Organization
type:Person
name:Eduardo H Charreau
affiliation:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490
address:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490, Buenos Aires, Argentina
type:PostalAddress
type:Organization
type:Person
name:Patricia V Elizalde
affiliation:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490
address:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490, Buenos Aires, Argentina
type:PostalAddress
type:Organization
email:[email protected]
type:Person
isAccessibleForFree:
hasPart:
isAccessibleForFree:
cssSelector:.main-content
type:WebPageElement
["Periodical","PublicationVolume"]:
name:Oncogene
issn:
1476-5594
0950-9232
volumeNumber:23
Organization:
name:Nature Publishing Group UK
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490
address:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490, Buenos Aires, Argentina
type:PostalAddress
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490
address:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490, Buenos Aires, Argentina
type:PostalAddress
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490
address:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490, Buenos Aires, Argentina
type:PostalAddress
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490
address:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490, Buenos Aires, Argentina
type:PostalAddress
name:Servicio de PatologÃa, Sanatorio Mater Dei
address:
name:Servicio de PatologÃa, Sanatorio Mater Dei, Buenos Aires, Argentina
type:PostalAddress
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490
address:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490, Buenos Aires, Argentina
type:PostalAddress
name:Instituto de Investigaciones en IngenierÃa Genética y BiologÃa Molecular (INGEBI)
address:
name:Instituto de Investigaciones en IngenierÃa Genética y BiologÃa Molecular (INGEBI), Argentina
type:PostalAddress
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490
address:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490, Buenos Aires, Argentina
type:PostalAddress
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490
address:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490, Buenos Aires, Argentina
type:PostalAddress
ImageObject:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
name:Mariana Salatino
affiliation:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490
address:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490, Buenos Aires, Argentina
type:PostalAddress
type:Organization
name:Roxana Schillaci
affiliation:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490
address:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490, Buenos Aires, Argentina
type:PostalAddress
type:Organization
name:Cecilia J Proietti
affiliation:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490
address:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490, Buenos Aires, Argentina
type:PostalAddress
type:Organization
name:Romina Carnevale
affiliation:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490
address:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490, Buenos Aires, Argentina
type:PostalAddress
type:Organization
name:Isabel Frahm
affiliation:
name:Servicio de PatologÃa, Sanatorio Mater Dei
address:
name:Servicio de PatologÃa, Sanatorio Mater Dei, Buenos Aires, Argentina
type:PostalAddress
type:Organization
name:Alfredo A Molinolo
affiliation:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490
address:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490, Buenos Aires, Argentina
type:PostalAddress
type:Organization
name:Adolfo Iribarren
affiliation:
name:Instituto de Investigaciones en IngenierÃa Genética y BiologÃa Molecular (INGEBI)
address:
name:Instituto de Investigaciones en IngenierÃa Genética y BiologÃa Molecular (INGEBI), Argentina
type:PostalAddress
type:Organization
name:Eduardo H Charreau
affiliation:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490
address:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490, Buenos Aires, Argentina
type:PostalAddress
type:Organization
name:Patricia V Elizalde
affiliation:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490
address:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490, Buenos Aires, Argentina
type:PostalAddress
type:Organization
email:[email protected]
PostalAddress:
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490, Buenos Aires, Argentina
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490, Buenos Aires, Argentina
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490, Buenos Aires, Argentina
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490, Buenos Aires, Argentina
name:Servicio de PatologÃa, Sanatorio Mater Dei, Buenos Aires, Argentina
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490, Buenos Aires, Argentina
name:Instituto de Investigaciones en IngenierÃa Genética y BiologÃa Molecular (INGEBI), Argentina
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490, Buenos Aires, Argentina
name:Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de BiologÃa y Medicina Experimental (IBYME), CONICET, Obligado 2490, Buenos Aires, Argentina
WebPageElement:
isAccessibleForFree:
cssSelector:.main-content
External Links {🔗}(31)
- How much income does https://link.springer.com/article/10.1038/sj.onc.1207659?utm_source=nature&utm_medium=referral&utm_campaign=buyArticle have?
- What's the financial gain of https://citation-needed.springer.com/v2/references/10.1038/sj.onc.1207659?format=refman&flavour=references?
- What are the earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Mariana%20Salatino?
- Profit of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Mariana%20Salatino%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- Earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Roxana%20Schillaci
- Monthly income for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Roxana%20Schillaci%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- Revenue of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Cecilia%20J%20Proietti
- Get to know what's the income of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Cecilia%20J%20Proietti%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- What's the financial gain of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Romina%20Carnevale?
- Monthly income for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Romina%20Carnevale%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Isabel%20Frahm income
- What's the monthly money flow for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Isabel%20Frahm%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Alfredo%20A%20Molinolo earn?
- What are the earnings of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Alfredo%20A%20Molinolo%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Adolfo%20Iribarren pull in monthly?
- How much money does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Adolfo%20Iribarren%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en generate?
- How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Eduardo%20H%20Charreau earn?
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Eduardo%20H%20Charreau%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en bring in each month?
- What's the monthly money flow for https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Patricia%20V%20Elizalde?
- How much money does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Patricia%20V%20Elizalde%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en generate?
- https://s100.copyright.com/AppDispatchServlet?title=Inhibition%20of%20in%20vivo%20breast%20cancer%20growth%20by%20antisense%20oligodeoxynucleotides%20to%20type%20I%20insulin-like%20growth%20factor%20receptor%20mRNA%20involves%20inactivation%20of%20ErbBs%2C%20PI-3K%2FAkt%20and%20p42%2Fp44%20MAPK%20signaling%20pathways%20but%20not%20modulation%20of%20progesterone%20receptor%20activity&author=Mariana%20Salatino%20et%20al&contentID=10.1038%2Fsj.onc.1207659©right=Springer%20Nature%20Limited&publication=0950-9232&publicationDate=2004-05-03&publisherName=SpringerNature&orderBeanReset=true income
- Financial intake of https://citation-needed.springer.com/v2/references/10.1038/sj.onc.1207659?format=refman&flavour=citation
- How much revenue does https://doi.org/10.1007/s12672-018-0356-3 bring in?
- Learn how profitable https://doi.org/10.1038/onc.2014.272 is on a monthly basis
- How much money does https://doi.org/10.1007/s10549-013-2528-8 make?
- How much income does https://doi.org/10.1186/bcr3211 have?
- How much money does https://doi.org/10.1186/bcr3187 make?
- How much does https://www.protocols.io/ pull in monthly?
- What's the income of https://www.natureindex.com/?
- What's the financial outcome of http://www.naturechina.com?
- How much does https://www.natureasia.com/ja-jp gross monthly?
Analytics and Tracking {📊}
- Google Tag Manager
Libraries {📚}
- Prism.js
- Zoom.js
Emails and Hosting {✉️}
Mail Servers:
- mxa-002c5801.gslb.pphosted.com
- mxb-002c5801.gslb.pphosted.com
Name Servers:
- pdns1.ultradns.net
- pdns2.ultradns.net
- pdns3.ultradns.org
- pdns4.ultradns.org
- pdns5.ultradns.info
- pdns6.ultradns.co.uk
CDN Services {📦}
- Crossref